November 16, 2019
UMM fundraising campaign is live
Ultrasonic Medical Mapping, Inc. (UMM) has actively campaigning to raise funds for tthe construction and testing of clinical prototypes. More information is available on the company’s webpage www.umedmap.com/investors.
September 16, 2019
UMM converts from LLC to C-corp
Ultrasonic Medical Mapping, LLC (UMM) executed a statutory conversion to reorganize from an LLC to a Delaware corporation. This change will facilitate UMM’s upcoming offering by removing a limitation on the number of investors allowed to participate.
April 24, 2019
UMM adds to Medical Advisory Board
Working with PANCAN, Ultrasonic Medical Mapping, LLC (UMM) finalized its Medical Advisory board and established parameters for a clinical study to be conducted upon completion of its clinical ready prototype.
January 30th, 2019
UMM Validates $9 Billion Screening Market for Pancreatic Cancer
The results from an extensive market survey effort by Ultrasonic Medical Mapping, LLC (UMM) have established the viability of a mass screening tool for pancreatic cancer. UMM estimates the annual market potential to be in excess of $9 Billion annually in the United States alone. This is in addition to the $37 Billion spent annually on diagnostic imaging as no technology currently exists that is suitable for mass screening.
January 15, 2019
UMM welcomes Dr. Lynn Matrisian
Ultrasonic Medical Mapping, LLC (UMM), a closely held startup dedicated to bringing low frequency ultrasonic diagnostics into the medical space for early cancer detection welcomes Dr. Lynn Matrisian, PhD of PANCAN as a Science Advisor. Dr. Matrisian’s work with pancreatic cancer and relationships with leading medical providers will be invaluable to UMM’s goals.
December 18, 2018
UMM adds Reece Tomlinson to Leadership Team
Ultrasonic Medical Mapping, LLC (UMM), added Reece Tomlinson of RWT Growth to its management team as Director of Business Development. Reece brings a depth of experience to bear and will be an invaluable asset going forward.
November 28, 2018
UMM Establishes Relationship with PANCAN
Ultrasonic Medical Mapping, LLC (UMM) is pleased to announce our new working relationship the Pancreatic Cancer Action Network, PANCAN, to further its ability to properly address the current inherent problems faced by lack of capable and cost-effective pancreatic cancer detection tools.
October 23rd, 2018
UMM Expands Focus to Include Pancreatic Cancer
Ultrasonic Medical Mapping, LLC (UMM) announced the first expansion of its core technology offering to encompass additional tissue types, focusing first on pancreatic cancer detection. Pancreatic cancer was chosen as a core target due to the fact that pancreatic cancer patient’s low survival rate is driven almost entirely by the lack of early detection.
June 10th, 2018
UMM Selects Singularis Solutions as Engineering Partner
Ultrasonic Medical Mapping, LLC (UMM) is pleased to announce that Philadelphia-based Singularis Solutions has been chosen as the engineering partner to build out the next generation clinical prototype. This selection, made by UMM leadership, occurred after an extensive vetting process where several medical device design and engineering firms were evaluated and vetted.
March 5, 2018
Ultrasonic Medical Mapping announces results of Gen 5 preclinical testing
Ultrasonic Medical Mapping, LLC (UMM) announced the results of its Gen 5 preclinical testing. Using a custom “dense breast” phantom created by CIRS as a target, UMM performed comparative testing against all current modalities (MRI/CT/2D Mx/3D Mx). The low frequency ultrasound system produced more detectable events than all competing technologies in a difficult target environment.
December 4, 2017
UMM Announces Final Closing of Seed Funding Round
Ultrasonic Medical Mapping, LLC, a closely held startup dedicated to bringing low frequency ultrasonic mapping into the medical space announced the final closing of their seed funding round. Managing Member David Johnson indicated that this funding would be used for final enhancement and testing of the proprietary preclinical prototype.
November 20, 2016
USPTO approves UMM Claims
USPTO grants Ultrasonic Medical Mapping, LLC (UMM) exclusive rights to use low frequency ultrasound for the collection of diagnostic data in a medical capacity. As granted, UMM’s patent provides broad protection against potential competition. Continuation Claims have been filed to further enhance this protection.